How to Help Your Patients Find Gimoti In Stock: A Provider's Guide

Many providers who prescribe Gimoti (metoclopramide nasal spray) discover that their patients are not actually receiving it. The most common reason: the prescription was sent to a retail pharmacy. This guide walks through every step of the Gimoti fulfillment process so you can set your patients up for success from the moment you write the prescription.

The Single Most Important Step: Always Route to ASPN Pharmacies

Gimoti is exclusively dispensed through ASPN Pharmacies. If your EHR or staff accidentally sends the Rx to a retail pharmacy, the patient will be unable to fill it. Train your team on this:

ASPN Pharmacies phone: 1-844-2GIMOTI (1-844-244-6684)

Fax: 1-888-661-9657

NCPDP#: 3147863 | NPI: 1538590690 | ZIP: 07039

Consider adding ASPN Pharmacies as a "preferred pharmacy" in your EHR for Gimoti. ASPN also has a prescriber portal (through gimotirxhcp.com) that allows electronic prescription management and PA tracking.

Before You Prescribe: Pre-Screening for Contraindications

Before routing a Gimoti prescription, screen for contraindications that would make the medication inappropriate regardless of availability:

Prior tardive dyskinesia or dystonic reaction to metoclopramide — absolutely contraindicated.

Parkinson's disease — contraindicated.

CrCl < 60 mL/min or Child-Pugh B/C hepatic impairment — not recommended.

Known CYP2D6 poor metabolizer or concurrent strong CYP2D6 inhibitor use — not recommended.

Concurrent antipsychotic use — additive extrapyramidal risk; use with caution.

GI hemorrhage, mechanical obstruction, or perforation — avoid.

Setting Patients Up for PA Success

Most commercial insurers require prior authorization before covering Gimoti. PA approvals are more likely when your documentation includes:

Confirmed diagnosis of diabetic gastroparesis — ideally with 4-hour gastric emptying study results (AGA now recommends 4-hour studies).

Documented prior trial of oral metoclopramide with specific dates, doses, and the reason for discontinuation (inadequate response or intolerable side effects). Note: drug samples and discount card trials are excluded by most plans.

Clinical rationale for nasal route (e.g., vomiting limiting oral absorption, dysphagia, erratic oral response).

Attestation of your awareness of and patient counseling on the boxed warning for tardive dyskinesia.

ASPN's PA Management Process

Once the prescription arrives at ASPN, they manage the PA process electronically:

ASPN initiates an ePA through CoverMyMeds or equivalent platforms, or sends PA questions by fax.

Your staff completes the PA questionnaire electronically or by fax.

ASPN follows up with the payer every 2 business days until a decision is reached (approximately 7 business days).

If PA is denied, ASPN can initiate an appeal with a Level of Medical Necessity (LMN) letter (approximately 30 days for determination).

Savings Programs: How Your Patients Pay

$0 copay: Eligible patients with qualifying commercial insurance pay $0 through Evoke Pharma's savings program.

$20 copay: Available to patients whose commercial insurance denies coverage or who lack commercial insurance.

Medicare/Medicaid: Patients with government insurance are not eligible for the manufacturer copay program but may have coverage through their specific plan. Numerous fee-for-service and managed care Medicare/Medicaid plans cover Gimoti.

What to Tell Your Patients at the Point of Prescribing

Set patient expectations at the visit to avoid confusion later:

"This medication is only available from a specialty pharmacy called ASPN Pharmacies — not your local pharmacy."

"Save the number 1-844-244-6684 in your phone as ASPN Pharmacies — they will text you within 24 hours."

"If your insurance requires prior authorization, expect the process to take up to one week — but you can start for $20 while it's being processed."

"Use this medication for a maximum of 8 weeks at a time and no more than 12 weeks total (all metoclopramide products combined)."

Monitoring Patients on Gimoti

Schedule follow-up at 4–8 weeks to assess symptom response and tolerability. Screen for early signs of extrapyramidal symptoms or tardive dyskinesia at each visit. Track the total cumulative duration of metoclopramide exposure across all formulations in the patient record.

How medfinder Supports Your Patients Beyond Gimoti

Patients with diabetic gastroparesis typically take several medications — insulin analogs, metformin, and other therapies in addition to Gimoti. Access barriers at any one pharmacy can disrupt their complete regimen. medfinder for providers helps your patients confirm prescription availability at pharmacies near them, reducing access friction across their entire medication list.

Also see: Gimoti Shortage: What Providers and Prescribers Need to Know in 2026 for additional clinical guidance.